DK3237001T5 - Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer - Google Patents

Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer Download PDF

Info

Publication number: DK3237001T5
Authority: DK; Denmark
Prior art keywords: antibodies; liquid compositions; pharmaceutical products; stable liquid; stable
Prior art date: 2014-12-22

Application number

DK15823805.5T

Other languages

English (en)

Other versions

DK3237001T3 (da

Inventor

Susanne Joerg

Kathrin Serno-Schersch

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-22

Filing date

2015-12-21

Publication date

2024-10-14

2015-12-21 Application filed by Novartis Ag filed Critical Novartis Ag

2024-04-15 Publication of DK3237001T3 publication Critical patent/DK3237001T3/da

2024-10-14 Application granted granted Critical

2024-10-14 Publication of DK3237001T5 publication Critical patent/DK3237001T5/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK15823805.5T 2014-12-22 2015-12-21 Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer DK3237001T5 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462095210P	2014-12-22	2014-12-22
PCT/IB2015/059836 WO2016103153A1 (en)	2014-12-22	2015-12-21	Pharmaceutical products and stable liquid compositions of il-17 antibodies

Publications (2)

Publication Number	Publication Date
DK3237001T3 DK3237001T3 (da)	2024-04-15
DK3237001T5 true DK3237001T5 (da)	2024-10-14

Family

ID=55135471

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15823805.5T DK3237001T5 (da)	2014-12-22	2015-12-21	Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer

Country Status (31)

Country	Link
US (3)	US11801300B2 (da)
EP (2)	EP4372005A3 (da)
JP (4)	JP6770974B2 (da)
KR (4)	KR20250008977A (da)
CN (5)	CN107257692B (da)
AR (1)	AR103173A1 (da)
AU (1)	AU2015370522B2 (da)
BR (1)	BR112017013240A2 (da)
CA (1)	CA2971800A1 (da)
CL (1)	CL2017001638A1 (da)
CO (1)	CO2017005950A2 (da)
DK (1)	DK3237001T5 (da)
EA (1)	EA033824B1 (da)
EC (1)	ECSP17047155A (da)
ES (1)	ES2976305T3 (da)
FI (1)	FI3237001T3 (da)
HR (1)	HRP20240253T1 (da)
HU (1)	HUE066126T2 (da)
IL (3)	IL310604A (da)
LT (1)	LT3237001T (da)
MX (1)	MX2017008412A (da)
PE (1)	PE20170952A1 (da)
PH (1)	PH12017500966A1 (da)
PL (1)	PL3237001T3 (da)
PT (1)	PT3237001T (da)
RS (1)	RS65387B1 (da)
SG (1)	SG11201703828VA (da)
SI (1)	SI3237001T1 (da)
TN (1)	TN2017000181A1 (da)
TW (1)	TW201641104A (da)
WO (1)	WO2016103153A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR103172A1 (es) *	2014-12-22	2017-04-19	Novartis Ag	Reducción selectiva de residuos de cisteina en anticuerpos il-17
EP3487881B1 (en) *	2016-07-19	2024-08-21	Novartis AG	Methods of treating new-onset plaque type psoriasis using il-17 antagonists
TW202348250A (zh) *	2017-07-24	2023-12-16	美商再生元醫藥公司	穩定化之抗體組合物及其製法
US20210179702A1 (en) *	2017-11-02	2021-06-17	Novartis Ag	Method of treating tendinopathy using interleukin-17 (il-17)
GB201719447D0 (en) *	2017-11-23	2018-01-10	Ucb Biopharma Sprl	Pharmaceutical composition
CN109350740B (zh) *	2017-11-30	2023-06-20	百奥泰生物制药股份有限公司	一种治疗il-6相关疾病的人源化抗体的液体制剂
CN111303283A (zh)	2018-12-12	2020-06-19	上海君实生物医药科技股份有限公司	抗il-17a抗体及其应用
US20210346380A1 (en) *	2018-12-25	2021-11-11	Sol-Gel Technologies Ltd.	Treatment of skin disorders with compositions comprising an egfr inhibitor
CR20210435A (es)	2019-02-18	2021-09-20	Lilly Co Eli	Formulación de anticuerpos terapéuticos
RU2754760C2 (ru) *	2019-04-02	2021-09-07	Закрытое Акционерное Общество "Биокад"	Водная фармацевтическая композиция анти-il17a антитела и ее применение
CN110179746A (zh) *	2019-05-17	2019-08-30	通化东宝生物科技有限公司	一种稳定的苏金单抗注射剂及其制备方法
CN110124030A (zh) *	2019-06-10	2019-08-16	通化东宝生物科技有限公司	一种苏金单抗注射液及其制备方法
KR20220066318A (ko)	2019-09-20	2022-05-24	노파르티스 아게	인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
CN110585430B (zh) *	2019-09-29	2023-09-08	华博生物医药技术（上海）有限公司	一种人源化抗人il-17a单克隆抗体的药物组合物
IL292926A (en)	2019-11-19	2022-07-01	Novartis Ag	Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
CN112915201B (zh) *	2019-12-06	2023-06-27	珠海市丽珠单抗生物技术有限公司	包含抗il-17抗体的液体制剂
CN115279396A (zh) *	2020-03-30	2022-11-01	四川泸州步长生物制药有限公司	人类甲状旁腺激素(pth)的制剂及用于生产其的方法
US20240101659A1 (en) *	2020-11-25	2024-03-28	Dr. Reddy’S Laboratories Limited	Stable therapeutic protein formulation and methods of making the same
CN117529506A (zh) *	2021-06-11	2024-02-06	海南先声药业有限公司	抗人il-17抗体和taci的双功能融合蛋白分子
CN113999300B (zh) *	2021-12-13	2022-09-13	青岛润达生物科技有限公司	一种高效提取卵黄抗体的复合沉降剂及方法
CN114452383B (zh) *	2022-02-17	2023-06-06	中国中医科学院中药研究所	司库奇尤单抗在治疗糖尿病溃疡中的用途
WO2024156841A1 (en)	2023-01-27	2024-08-02	Fresenius Kabi Deutschland Gmbh	Biopharmaceutical composition
EP4406553A1 (en)	2023-01-27	2024-07-31	Fresenius Kabi Deutschland GmbH	Stable secukinumab biopharmaceutical composition
KR20240141083A (ko) *	2023-03-17	2024-09-25	(주)셀트리온	안정한 약제학적 제제 및 완제의약품의 제조공정
CN119405595A (zh) *	2024-03-14	2025-02-11	程度胜	含重组人白细胞介素-2的药物组合物、药物制剂及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
EP2261335B1 (en)	1998-11-27	2017-06-14	UCB Pharma S.A.	Compositions and methods for increasing bone mineralisation
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
JP2003510368A (ja)	1999-10-04	2003-03-18	カイロンコーポレイション	安定化された液体のポリペプチド含有薬学的組成物
US20030104996A1 (en) *	2001-08-30	2003-06-05	Tiansheng Li	L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
ES2392073T3 (es)	2001-11-08	2012-12-04	Abbott Biotherapeutics Corp.	Formulación farmacéutica líquida estable de anticuerpos IGG
WO2003073991A2 (en)	2002-03-01	2003-09-12	Celltech R & D, Inc.	Methods to increase or decrease bone density
WO2003106657A2 (en)	2002-06-14	2003-12-24	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
US20040033228A1 (en) *	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004262640B2 (en)	2003-06-16	2010-12-23	Ucb Manufacturing, Inc.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en)	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
SV2008002394A (es) *	2005-01-28	2008-02-08	Wyeth Corp	Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
EP1868646A2 (en) *	2005-03-08	2007-12-26	Pharmacia & Upjohn Company LLC	Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
WO2007117749A2 (en)	2006-01-31	2007-10-18	Novartis Ag	Il-17 antagonistic antibodies fpr treating cancer
EP2094731A2 (en)	2006-11-10	2009-09-02	UCB Pharma S.A.	Anti human sclerostin antibodies
EP2097450A2 (en)	2006-11-10	2009-09-09	Amgen Inc.	Antibody-based diagnostics and therapeutics
WO2008092894A1 (en)	2007-02-02	2008-08-07	Novartis Ag	Modulators of sclerostin binding partners for treating bone-related disorders
MY149129A (en)	2007-03-20	2013-07-15	Lilly Co Eli	Anti-sclerostin antibodies
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EA201070740A1 (ru)	2007-12-14	2010-12-30	Эмджен Инк.	Способ лечения перелома кости антителами против склеростина
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
US20120183531A1 (en) *	2009-07-14	2012-07-19	Biogen Idee Ma Inc	Methods for Inhibiting Yellow Color Formation in a Composition
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
EP3299390A1 (en) *	2010-10-08	2018-03-28	Novartis AG	Methods of treating psoriasis using il-17 antagonists
MX362591B (es) *	2010-11-05	2019-01-25	Novartis Ag	Uso de antagonistas de il-17.
MX2014006158A (es) *	2011-11-21	2014-06-19	Novartis Ag	Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
WO2013134052A1 (en) *	2012-03-07	2013-09-12	Eli Lilly And Company	Il-17 antibody formulation
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations

2015
- 2015-12-18 AR ARP150104193A patent/AR103173A1/es unknown
- 2015-12-21 KR KR1020247043157A patent/KR20250008977A/ko active Search and Examination
- 2015-12-21 CN CN201580076632.9A patent/CN107257692B/zh active Active
- 2015-12-21 TN TN2017000181A patent/TN2017000181A1/en unknown
- 2015-12-21 US US15/538,257 patent/US11801300B2/en active Active
- 2015-12-21 KR KR1020237043038A patent/KR102749243B1/ko not_active Application Discontinuation
- 2015-12-21 FI FIEP15823805.5T patent/FI3237001T3/fi active
- 2015-12-21 PT PT158238055T patent/PT3237001T/pt unknown
- 2015-12-21 AU AU2015370522A patent/AU2015370522B2/en active Active
- 2015-12-21 RS RS20240422A patent/RS65387B1/sr unknown
- 2015-12-21 HR HRP20240253TT patent/HRP20240253T1/hr unknown
- 2015-12-21 CN CN202111362275.6A patent/CN113876947A/zh active Pending
- 2015-12-21 TW TW104143009A patent/TW201641104A/zh unknown
- 2015-12-21 HU HUE15823805A patent/HUE066126T2/hu unknown
- 2015-12-21 PE PE2017001096A patent/PE20170952A1/es not_active Application Discontinuation
- 2015-12-21 SI SI201531997T patent/SI3237001T1/sl unknown
- 2015-12-21 ES ES15823805T patent/ES2976305T3/es active Active
- 2015-12-21 LT LTEPPCT/IB2015/059836T patent/LT3237001T/lt unknown
- 2015-12-21 BR BR112017013240A patent/BR112017013240A2/pt not_active Application Discontinuation
- 2015-12-21 CN CN202111362173.4A patent/CN114452380A/zh active Pending
- 2015-12-21 EP EP24155578.8A patent/EP4372005A3/en active Pending
- 2015-12-21 MX MX2017008412A patent/MX2017008412A/es unknown
- 2015-12-21 CN CN202111362326.5A patent/CN114452381A/zh active Pending
- 2015-12-21 KR KR1020237007135A patent/KR102614921B1/ko active IP Right Grant
- 2015-12-21 DK DK15823805.5T patent/DK3237001T5/da active
- 2015-12-21 SG SG11201703828VA patent/SG11201703828VA/en unknown
- 2015-12-21 EP EP15823805.5A patent/EP3237001B1/en active Active
- 2015-12-21 PL PL15823805.5T patent/PL3237001T3/pl unknown
- 2015-12-21 EA EA201791422A patent/EA033824B1/ru not_active IP Right Cessation
- 2015-12-21 IL IL310604A patent/IL310604A/en unknown
- 2015-12-21 JP JP2017551391A patent/JP6770974B2/ja active Active
- 2015-12-21 CA CA2971800A patent/CA2971800A1/en active Pending
- 2015-12-21 IL IL287328A patent/IL287328B2/en unknown
- 2015-12-21 WO PCT/IB2015/059836 patent/WO2016103153A1/en active Application Filing
- 2015-12-21 CN CN202111364411.5A patent/CN113855800A/zh active Pending
- 2015-12-21 KR KR1020177016756A patent/KR102506173B1/ko active IP Right Grant
2017
- 2017-05-07 IL IL252141A patent/IL252141B/en unknown
- 2017-05-25 PH PH12017500966A patent/PH12017500966A1/en unknown
- 2017-06-15 CO CONC2017/0005950A patent/CO2017005950A2/es unknown
- 2017-06-21 CL CL2017001638A patent/CL2017001638A1/es unknown
- 2017-07-20 EC ECIEPI201747155A patent/ECSP17047155A/es unknown
2019
- 2019-08-16 JP JP2019149368A patent/JP6878524B2/ja active Active
2021
- 2021-04-27 JP JP2021074603A patent/JP2021119165A/ja not_active Withdrawn
2023
- 2023-06-09 JP JP2023095510A patent/JP2023113906A/ja active Pending
- 2023-10-04 US US18/481,213 patent/US20240173404A1/en active Pending
2024
- 2024-09-03 US US18/823,573 patent/US20240415961A1/en active Pending

Also Published As

Publication number	Publication date
AU2015370522B2 (en)	2018-05-10
ES2976305T3 (es)	2024-07-29
KR20230173742A (ko)	2023-12-27
US20240173404A1 (en)	2024-05-30
PE20170952A1 (es)	2017-07-13
SI3237001T1 (sl)	2024-06-28
CN114452381A (zh)	2022-05-10
TW201641104A (zh)	2016-12-01
US20170368174A1 (en)	2017-12-28
EA033824B1 (ru)	2019-11-29
JP6770974B2 (ja)	2020-10-21
US20240415961A1 (en)	2024-12-19
CN113876947A (zh)	2022-01-04
LT3237001T (lt)	2024-04-25
IL252141A0 (en)	2017-07-31
PL3237001T3 (pl)	2024-06-24
EP3237001B1 (en)	2024-02-07
IL252141B (en)	2021-12-01
FI3237001T3 (fi)	2024-03-22
DK3237001T3 (da)	2024-04-15
EP4372005A3 (en)	2024-07-31
ECSP17047155A (es)	2019-02-28
CN107257692B (zh)	2021-11-19
HUE066126T2 (hu)	2024-07-28
IL287328B2 (en)	2024-07-01
JP2020011963A (ja)	2020-01-23
EP4372005A2 (en)	2024-05-22
SG11201703828VA (en)	2017-07-28
IL287328B1 (en)	2024-03-01
CO2017005950A2 (es)	2017-08-31
JP6878524B2 (ja)	2021-05-26
KR102749243B1 (ko)	2025-01-03
JP2021119165A (ja)	2021-08-12
AU2015370522A1 (en)	2017-06-01
CN113855800A (zh)	2021-12-31
MX2017008412A (es)	2017-10-19
PT3237001T (pt)	2024-04-16
CN114452380A (zh)	2022-05-10
EP3237001A1 (en)	2017-11-01
US11801300B2 (en)	2023-10-31
KR20250008977A (ko)	2025-01-16
BR112017013240A2 (pt)	2018-02-06
PH12017500966A1 (en)	2017-10-18
IL310604A (en)	2024-04-01
IL287328A (en)	2021-12-01
CL2017001638A1 (es)	2018-04-13
CN107257692A (zh)	2017-10-17
RS65387B1 (sr)	2024-04-30
KR20230037677A (ko)	2023-03-16
AR103173A1 (es)	2017-04-19
JP2018502910A (ja)	2018-02-01
CA2971800A1 (en)	2016-06-30
KR20170095878A (ko)	2017-08-23
HRP20240253T1 (hr)	2024-05-10
JP2023113906A (ja)	2023-08-16
WO2016103153A1 (en)	2016-06-30
EA201791422A1 (ru)	2017-10-31
KR102506173B1 (ko)	2023-03-07
KR102614921B1 (ko)	2023-12-19
TN2017000181A1 (en)	2018-10-19

Publication	Publication Date	Title
DK3237001T5 (da)	2024-10-14	Farmaceutiske produkter og stabile flydende sammensætninger af il-17-antistoffer
DK3506884T4 (da)	2025-01-02	Sammensætninger til indgivelse af medicin og anvendelser deraf
DK3370770T3 (da)	2021-03-01	Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
DK3690056T5 (da)	2024-08-26	Fremgangsmåder og produkter til fremstilling og indgivelse af nukleinsyre
DK3039146T3 (da)	2020-08-10	Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose
DK3303395T3 (da)	2020-01-27	Anti-cd40-antistoffer og anvendelser deraf
DK3479819T5 (da)	2024-09-09	Stabilt væskeformigt farmaceutisk præparat
DK3116909T3 (da)	2020-01-20	Antistofmolekyler til lag-3 og anvendelser deraf
DK3237436T3 (da)	2019-08-12	Peptider og nanopartikler til intracellulær indgivelse af molekyler
BR112016026879A2 (pt)	2017-08-15	Composição farmacêutica líquida
DK3364958T3 (da)	2023-04-11	Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
DK3102184T3 (da)	2019-05-06	Stabile formuleringer af peptider og fremgangsmåder til fremstilling
DK3099800T3 (da)	2021-01-11	Ekspression og oprensning af crm197 og beslægtede proteiner
DK3532029T3 (da)	2021-06-07	Flydende farmaceutisk sammensætning
DK3129019T3 (da)	2019-10-07	Medicinsk anvendelse af artemisinin-forbindelser og gephyrin-agonister
BR112017008125A2 (pt)	2018-06-19	redução da viscosidade de formulações farmacêuticas
DK3237054T3 (da)	2019-11-25	Indretning til fremstilling og påføring af en medicinsk substans
DK3380525T3 (da)	2024-01-29	Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK2958573T3 (da)	2019-08-05	Farmaceutiske formuleringer af nitrit og anvendelser deraf
DK3242564T3 (da)	2021-11-08	Fremgangsmåde til fremstilling af bløde holdbare produkter
DK3302483T3 (da)	2020-06-15	Farmaceutiske sammensætninger og anvendelse deraf
DK3503885T3 (da)	2022-06-20	Farmaceutisk præparat og fremgangsmåder til anvendelse heraf
DK2957280T3 (da)	2019-07-22	Farmaceutisk faststofsammensætning af cytisin og fremgangsmåde til fremstilling deraf
EP3439650A4 (en)	2019-12-11	LIQUID PHOSPHAPLATIN FORMULATIONS
DK3125839T3 (da)	2021-01-18	Indretning og fremgangsmåde til dråbevis administration af en væske